

The Interaction Effects of pri-let-7a-1 rs10739971 with *PGC* and *ERCC6* Gene Polymorphisms in Gastric Cancer and Atrophic Gastritis

Qian Xu^{1,2}, Jing-wei Liu^{1,2}, Cai-yun He^{1,2}, Li-ping Sun^{1,2}, Yue-hua Gong^{1,2}, Jing-jing Jing^{1,2}, Cheng-zhong Xing^{1,2}, Yuan Yuan^{1,2}*

1 Tumor Etiology and Screening Department of Cancer Institute and General Surgery, the First Affiliated Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China, 2 Key Laboratory of Cancer Etiology and Prevention, China Medical University, Liaoning Provincial Education Department, Shenyang, Liaoning, People's Republic of China

Abstract

Background: The aim of this study was to investigate the interaction effects of pri-let-7a-1 rs10739971 with *pepsinogen C* (*PGC*) and *excision repair cross complementing group 6 (ERCC6)* gene polymorphisms and its association with the risks of gastric cancer and atrophic gastritis. We hoped to identify miRNA polymorphism or a combination of several polymorphisms that could serve as biomarkers for predicting the risk of gastric cancer and its precancerous diseases.

Methods: Sequenom MassARRAY platform method was used to detect polymorphisms of pri-let-7a-1 rs10739971 G \rightarrow A, *PGC* rs4711690 C \rightarrow G, *PGC* rs6458238 G \rightarrow A, *PGC* rs9471643 G \rightarrow C, and *ERCC6* rs1917799 in 471 gastric cancer patients, 645 atrophic gastritis patients and 717 controls.

Results: An interaction effect of pri-let-7a-1 rs10739971 polymorphism with *ERCC6* rs1917799 polymorphism was observed for the risk of gastric cancer ($P_{\text{interaction}} = 0.026$); and interaction effects of pri-let-7a-1 rs10739971 polymorphism with *PGC* rs6458238 polymorphism ($P_{\text{interaction}} = 0.012$) and *PGC* rs9471643 polymorphism ($P_{\text{interaction}} = 0.039$) were observed for the risk of atrophic gastritis.

Conclusion: The combination of pri-let-7a-1 rs10739971 polymorphism and *ERCC6* and *PGC* polymorphisms could provide a greater prediction potential than a single polymorphism on its own. Large-scale studies and molecular mechanism research are needed to confirm our findings.

Citation: Xu Q, Liu J-w, He C-y, Sun L-p, Gong Y-h, et al. (2014) The Interaction Effects of pri-let-7a-1 rs10739971 with PGC and ERCC6 Gene Polymorphisms in Gastric Cancer and Atrophic Gastritis. PLoS ONE 9(2): e89203. doi:10.1371/journal.pone.0089203

Editor: Xiaoping Miao, MOE Key Laboratory of Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, China

Received November 20, 2013; Accepted January 16, 2014; Published February 25, 2014

Copyright: © 2014 Xu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by grants from the National Key Basic Research Program of China (973 Program ref no. 2010CB529304), the National Natural Science Foundation of China (Ref No. 31200968), and the Science Technology Project in Liaoning Province (Ref No. 2011225002). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: yyuan3@mail.cmu.edu.cn

Introduction

Individuals with similar living habits and living in similar environments possess different risks of cancer. Identifying and predicting individuals at high risk of developing cancer can indicate the need for changing living habits. Single nucleotide polymorphisms (SNPs) play a pivotal role in predicting individuals with increased cancer risk. In recent years, polymorphisms of primiRNA were reported to be biomarkers for predicting cancer risk, such as pri-miR-34b/c rs4938723 polymorphism [1], pri-miR-218 rs11134527 polymorphism [2] and pri-miR-938 rs2505901 polymorphism [3]. Studies have found that the number of single gene polymorphisms was associated with the risk of gastric cancer [4]. However, gastric cancer is a complex multi-step disease with many genes involved, and single SNPs have limited ability to predict gastric cancer risk [5–7]. Several studies have reported that gene-gene interactions are more important than the main effect of

a single gene in complex diseases, such as cancers [7–9]. The basic research approach for gene-gene interactions is to investigate the combination of two or more polymorphisms with minor or no effects from previous single SNP studies [10,11]. However, most previous studies have focused on the predictive role of a single gene SNP and overlooked the potential application of gene-gene interactions

Currently, investigators mainly focus on gene SNP-SNP interactions, which can cause protein-protein interactions, and few studies have investigated interactions between miRNA polymorphisms and gene polymorphisms, which can cause protein-RNA interactions. miRNA has been reported to take part in the multi-gene network of gastric carcinogenesis [12]. The same miRNA was reported to regulate multiple target proteins, and the same proteins could be modulated by multiple miRNA [13]. As a result, the effects of miRNA and genes formed a network.

Our previous candidate gene association study investigated the association of pepsinogen C (PGC) and excision repair cross complementing group 6 (ERCC6) with the risk of gastric cancer, and found that PGC gene rs4711690 C→G, rs6458238 G→A, and rs9471643 G→C polymorphisms had protective effects against atrophic gastritis [4]. PGC had protective effects on the normal stomach and showed low expression in gastric cancer, and the loss of protection was associated with the occurrence of gastric cancer [14]. ERCC6 is a member of the DNA repair family which participates in the repairing DNA damage in carcinogenesis [15]. ERCC6 rs1917799 T>G polymorphism in the promoter region was associated with increased gastric cancer risk in a Chinese population [16]. Let-7a is a tumor suppressor, and recent studies found that the function of mature let-7a is closely related to the incidence and development of gastric cancer, and decreased expression of let-7a is associated with malignant biological behavior [17,18]. However, let-7a genetic variants were not examined for their associations and gastric cancer risks. Rs10739971 is a SNP located -559 bp upstream of let-7a-1, which might be a promoter region of let-7a-1. In the Hapmap database, the minimum allele frequency of rs10739971 is ≥5% in both Europeans and Asians. But whether there is an association between rs10739971 and disease risk, and interactions between rs10739971 and other polymorphisms, remain unknown. We hypothesized that the above-mentioned variants may be optimal candidates to investigate potential SNP-SNP interactions at two or more loci contributing to gastric cancer etiology.

In this case-control study using a Chinese population, we investigated the association of pri-let-7a-1 rs10739971 with gastric cancer risk, and the interaction effects of miRNA-let-7a-1 rs10739971 polymorphism and *PGC* and *ERCG6* polymorphisms in samples of the same group, and discuss its application prospects in gastric cancer and its precancerous diseases. To our knowledge, this is the first study attempting to assess potential SNP-SNP interactions of miRNA SNPs and gene SNPs at two or more loci implicated in gastric cancer susceptibility. We hoped to find combinations of gene-gene polymorphisms that could predict the risk of gastric cancer and its precancerous diseases, and to provide experimental evidence for the early diagnosis of gastric cancer.

Methods

Patients

In this study, a total of 1834 individuals, which included 471 gastric cancer patients, 646 atrophic gastritis patients and 717 controls, were retrospectively recruited from patients undergoing gastroscopy examination screening in Zhuanghe region and patients who underwent gastroscopy examination or gastric surgery at the First Affiliated Hospital of China Medical University, Liaoning Province, China between 2002 and 2011. Fasting venous blood was collected and all enrolled participants were diagnosed based on their gastroscopic and histopathological examinations. Gastric cancer was diagnosed based on WHO criteria, and atrophic gastritis and superficial gastritis were classified by Sydney's classification. Eligible controls were those participants with a normal stomach or only gastritis according to gastroscopic and pathological examinations and had no other diseases

The design of the study was approved by the Human Ethics Committee of China Medical University (Shenyang, China). Written informed consent was obtained from all participants. Medical histories (including age, sex, smoking, and alcohol consumption) were obtained by questionnaire and the records were computerized. Each individual involved in the study

Table 1. The basic messages of the subjects.

Variability	CON(%)	AG(%)	GC(%)	
	n = 717	n = 646	n = 471	
Gender	P<0.001			
Male	364(50.8)	366(56.7)	320(67.9)	
Female	353(49.2)	280(43.3)	151(32.1)	
Age	P<0.001			
Mean±SD	53.11 ± 9.83	55.06 ± 8.94	59.04±11.15	
Median	53	56	58	
Range	17–85	16–82	26-87	
H.pylori-IgG	P<0.001			
positive	151(21.1)	396(61.3)	245(52.0)	
negative	566(78.9)	250(38.7)	226(48.0)	

CON: controls; AG: atrophic gastritis; GC: gastric cancer. doi:10.1371/journal.pone.0089203.t001

provided written informed consent for epidemiological investigation. Detailed participant characteristics are summarized in Table 1.

Genomic DNA extracted

Genomic DNA was extracted using a previously described method with slight modification [19]. In brief, a frozen clot (500 µL) was added to 800 µL of TE buffer (triethanolamide), mixed well and centrifuged at $10,000 \times g$ for 5 min to disperse the clot. Following clot disruption, 400 µL of TE, 25 µL of 10% SDS and 5 µL of 20 mg/mL proteinase K were added and incubated at 37°C overnight. The supernatant was extracted and an equal volume of phenol was added. The tube was placed on a rotator for 15 min and then centrifuged at $10,000 \times g$ for 15 min. The supernatant was removed and a second extraction was performed with the addition of an equal volume of a mixture of phenol and chloroform (1:1). Following centrifugation, the supernatant was removed and a third extraction was performed with the addition of an equal volume of chloroform. Following centrifugation, the supernatant was absorbed and two volumes of protein precipitation solution (two volumes of absolute ethanol containing 10% 3 mol/L sodium acetate) were added and incubated for 2 h at -20° C. Each sample was centrifuged at $10,000 \times g$ for 10 min. After centrifugation, the resulting DNA pellet was rinsed with 75% ethanol and centrifuged at $10,000 \times g$ for 10 min. The 75% ethanol was decanted and the tube inverted on clean absorbent paper for 30 min. The resulting DNA was reconstituted in TE buffer and stored at -20° C until use.

SNP genotyping

DNA samples were diluted to working concentrations of 50 ng/ μL before genotyping. The assays, primer design, and genotyping of 29 polymorphism sites selected for a candidate gene associated study were all carried out by CapitalBio (Beijing, China) using Sequenom MassARRAY platform (Sequenom, San Diego, CA, USA) between May 2011 and December 2011 based on the manufacturer's directions[4,20]. Five of 29 polymorphisms were further selected for interaction analysis in the present study. To evaluate the quality of the genotyping, 5% repeated samples were genotyped and the results were 100% consistent.

Detection of H. pylori in serum

Serological tests for *H. pylori* were performed to check the status of H. pylori infection using ELISA (H. pylori-IgG ELISA kit, BIOHIT Plc, Helsinki, Finland), as described previously [21]. Positive was judged as the titer of H. pylori-IgG higher than 34EIU (the cut-off value given by the protocol). Briefly, serum samples were diluted 1:200 (5 μ L + 995 μ L) with diluent buffer and mixed well. Then 100 µL of blank solution, calibrators, controls and diluted samples were added to wells. The plate was covered with the incubation cover and incubated for 30 min at 37°C. After incubation, the wells were washed five times with 350 µL of diluted (1:100) washing buffer and the plate gently tapped several times on filter paper. Then 100 µL of mixed conjugate solution was added to the wells and incubated for 30 min at 37°C. After incubation, the wells were washed again and 100 µL of mixed substrate solution was added to the wells before incubating for 30 min at room temperature (20-25°C) in a dark environment. Lastly, 100 µL of mixed stop solution was added and the absorbance was read at 450 nm within 30 min.

Statistical analysis

All statistical analyses were carried out using SPSS 16.0 software (SPSS, Chicago, IL, USA). Pearson's χ^2 tests were used to evaluate differences between genders in case and control groups. ANOVA was performed to assess any differences between ages in the different groups. Likelihood ratio tests were performed to assess interaction effects on the risk of gastric cancer by comparing the model that only involved the main effects and the full model that also contained the interaction term. A *P*-value <0.05 for all two-sided tests was regarded as statistically significant.

Results

Main effect analyses of individual polymorphisms

In our previous study, we found that pri-let-7a-1 rs10739971 polymorphism was significantly associated with increased risk of atrophic gastritis (OR = 2.59, P=0.018) in the smaller study population but no significant association was found in the further validation study of a larger population (unpublished data); PGC rs4711690, rs6458238, and rs9471643 polymorphisms were significantly associated with increased risk of atrophic gastritis (P=0.093, OR=0.75; P=0.015, OR=0.73; P=0.033, OR=0.69, respectively) [4]; ERCC6 rs1917799 polymorphism was significantly associated with increased risk of gastric cancer (OR=1.38, P=0.035) [20].

The two-way interaction of pri-let-7a-1 rs10739971 and PGC, ERCC6 polymorphisms in the risk of gastric cancer/atrophic gastritis

To investigate whether gene polymorphisms and miRNA polymorphism had an interaction effect, we analyzed interactions between miRNA polymorphism and each gene polymorphism. We found that miRNA polymorphism and PGC and ERCC6 polymorphisms showed strong statistical association with gastric cancer or atrophic gastritis. Thus, we analyzed the interaction effect of pri-let-7a-1 rs10739971 polymorphism and PGC and ERCC6 polymorphisms, and its associations, with the risks of gastric cancer and atrophic gastritis. The results indicated that pri-let-7a-1 rs10739971 polymorphism and ERCC6 rs1917799 polymorphism had interaction effects for gastric cancer risk ($P_{\rm interaction} = 0.026$, Table 2). This SNP pair showed increased risk of gastric cancer (OR = 2.59, 95%CI = 1.12-5.97). Pri-let-7a-1 rs10739971 polymorphism and PGC rs65458238 and rs9471643 polymor

phisms had interaction effects for the risk of atrophic gastritis ($P_{\rm interaction} = 0.012$ and 0.039, respectively, Table 3). For the rs65458238 polymorphism, the SNP pair showed increased risk of atrophic gastritis (OR = 2.77, 95%CI = 1.25–6.13); while the other SNP pair showed decreased risk of atrophic gastritis (OR = 0.52, 95%CI = 0.28–0.97) for rs9471643 (Table 3).

SNP-SNP interactions involving multiple SNPs using logistic regression

We further investigated the SNP-SNP interaction involving three positive SNPs (pri-let-7a-1 rs10739971–PGC rs6458238–PGC rs9471643) and the result was statistically significant ($P_{\text{interaction}} = 0.001$, Table 4). The SNP combination showed increased risk of atrophic gastritis (OR = 23.55, 95%CI = 3.73–148.71).

Discussion

Polymorphisms of genes or miRNA might serve as potential biomarkers for predicting disease risk. Previous studies have mainly focused on the association of a single gene polymorphism with disease risk, and the risk was often of weak effect (OR<1.5). As for the combination of two or more SNP-SNP interactions, the risk was often of moderate (OR≥1.5) or strong effect (OR≥2) [4,10,22–24]. The present study, for the first time, investigated the interaction effects of miRNA polymorphism and *PGC* and *ERCC6* polymorphisms in a Northern Chinese population. The study aimed to provide experimental evidence for the early diagnosis and mechanisms of gastric cancer by finding combinations of gene-gene polymorphisms that could predict the risk of gastric cancer and its precancerous diseases.

Among the SNPs from our group investigated during our candidate gene association study, ERCC6 single-locus showed a weak effect for gastric cancer risk (OR = 1.46) [16]; the three PGC single-locus demonstrated a weak protective effect for atrophic gastritis risk (OR for rs4711690 = 0.75; OR for rs6458238 = 0.73; OR for rs9471643 = 0.69) [4]. We therefore hypothesized that these polymorphisms may be optimal candidates to investigate potential SNP-SNP interactions at two or more loci contributing to gastric cancer etiology. We performed the interaction effect analysis of miRNA polymorphism and gene polymorphisms and found three SNP-SNP pairs associated with diseases, of which the interaction of one pair (pri-let-7a-1 rs10739971–ERCC6 rs1917799) was associated with gastric cancer risk, and the interactions of the other two pairs (pri-let-7a-1 rs10739971-PGC rs65458238, and pri-let-7a-1 rs10739971-PGC rs9471643) were associated with atrophic gastritis risk. ERCC6 rs1917799 polymorphism and PGC rs6458238 and rs9471643 polymorphisms have been reported previously. In this study, we additionally analyzed pri-let-7a-1 rs10739971 polymorphism in the same group. The pair of pri-let-7a-1 rs10739971 polymorphism and ERCC6 rs1917799 polymorphism had an OR of their interaction of 2.59 for gastric cancer risk, which was greater than their individual single-locus effects of 0.92 and 1.07, respectively. Similarly, the pair of pri-let-7a-1 rs10739971 polymorphism and PGC rs6458238 polymorphism had an OR of their interaction of 2.77 for atrophic gastritis risk, which was larger than their individual single-locus effects of 0.74 and 1.23, respectively. The pair of pri-let-7a-1 rs10739971 polymorphism and PGC rs9471643 polymorphism had an OR of their interaction of 0.52 for atrophic gastritis risk. Interestingly, their individual single-locus effects were contrary to the above findings, with OR of 1.65 and 1.06, respectively, which deserves further independent replication of our findings.

Because pri-let-7a-1 rs10739971 polymorphism demonstrated interaction effects with both *PGC* SNPs on atrophic gastritis risk,

Table 2. The interaction of pri-let-7a-1 rs10739971 and ERCC6 rs1917799 polymorphisms in the risk of gastric cancer/atrophic gastritis^a.

		AG vs CON(n = 646 V	Vs. 717)	GC vs CON(n = 471	Vs. 717)	
		let-7a-1 rs10739971		let-7a-1 rs10739971		
		GG+AG	AA	GG+AG	AA	
ERCC6 rs1917799	9					
TT+GT	Case/Control	430/489	110/108	316/489	64/108	
	OR(95%CI)	1	1.16(0.86–1.56)	1	0.92(0.65-1.29)	
GG	Case/Control	88/100	18/20	69/100	22/20	
	OR(95%CI)	1.01(0.73–1.37)	1.02(0.53–1.96)	1.07(0.76–1.50)	1.70(0.91–3.17)	
		$P_{\text{interaction}} = 0.941$				

 $P_{\text{interaction}} = 0.026, OR(95\%CI) = 2.59(1.12-5.97)$

Note: ^a, *P* for interaction was used Logistic Regression adjusted by gender, age and *H.pylori* infection status. CON: controls; AG: atrophic gastritis; GC: gastric cancer. doi:10.1371/journal.pone.0089203.t002

we further carried out interaction analysis of the three positive polymorphisms. The results showed that the OR for the risk of atrophic gastritis was 23.55 (P=0.001). Generally, a single-locus has a weak effect (OR<1.5) on disease risk, and the combination of two or more SNP-SNP interactions often demonstrates a moderate (OR≥1.5) or a strong effect (OR≥2). In the present study, the OR of pri-let-7a-1 single locus was 1.61; the OR for interaction effects with ERCC6 and PGC were both more than 2; the combination of the three positive loci demonstrated an even higher OR of 23.55. These outcomes indicated the application prospects of a combination of two or more SNPs as potential biomarkers to predict disease risk.

Investigating the interaction effects of miRNA polymorphisms and gene polymorphisms will contribute to the comprehensive understanding of the gene network and the role of miRNA in the pathogenic process. Findings of SNP-SNP interactions often have underlying mechanisms rather than being merely statistical results [9]. The three pairs of SNPs indicated that miRNA might interact with genes in gastric carcinogenesis. PGC protein has a protective effect in the epithelium of the normal stomach, and its expression decreased in an atrophic gastritis group when compared with a normal group [14,25]. The exact role of PGC in atrophic gastritis is still not clear. ERCC6 is involved in the DNA repair pathway, and repeated DNA damage and repair may lead to cell carcinogenesis [15]. On the basis of the findings in the present study, it is reasonable to suggest that let-7a may participate in the processes of PGC inducing atrophic gastritis and ERCC6 inducing gastric cancer. According to results from miRNA target prediction software, there were possible binding sites of let-7a with 3'-UTR for both *PGC* and *ERCC6*. Whether the SNP-SNP interaction

Table 3. The interaction of pri-let-7a-1 rs10739971 and PGC polymorphisms in the risk of gastric cancer/atrophic gastritis^a.

		AG vs CON(n=646	Vs. 717)	GC vs CON(n = 471	Vs. 717)	
		let-7a-1 rs10739971		let-7a-1 rs10739971		
		GG+AG	AA	GG+AG	AA	
PGC rs4711	690					
CG+GG	Case/Control	202/247	53/55	161/247	34/55	
	OR(95%CI)	1	1.18(0.77–1.79)	1	0.95(0.59-1.52)	
СС	Case/Control	316/342	75/73	224/342	52/73	
	OR(95%CI)	1.13(0.89–1.44) 1.26(0.87–1.82)		1.01(0.77–1.30) 1.09(0.73–1.64)		
		$P_{\text{interaction}} = 0.630$		$P_{\text{interaction}} = 0.369$		
PGC rs6458	3238					
GA+AA	Case/Control	76/103	18/33	73/103	17/33	
	OR(95%CI)	1	0.74(0.39-1.41)	1	0.73(0.38-1.40)	
GG	Case/Control	442/486	110/95	312/486	69/95	
	OR(95%CI)	1.23(0.89-1.70)	1.57(1.05-2.35)	0.91(0.65-1.26)	1.03(0.67-1.58)	

 $P_{\text{interaction}} = \textbf{0.012,OR(95\%CI)} = \textbf{2.77(1.25-6.13)} P_{\text{interaction}} = 0.115 \text{PGC} \text{ rs} 9471643 \text{GC+CCcase/Control} 222/26166/47166/26138/47 \text{OR}(95\%\text{CI}) 11.65(1.09-2.50) 11.27(0.80-2.03) \text{GGCase/Control} 296/32862/81219/32848/81 \text{OR}(95\%\text{CI}) 1.06(0.84-1.35) 0.90(0.62-1.31) 1.05(0.81-1.36) 0.93(0.82-1.31) 1.05(0.81-1.36) 0.93(0.82-1.31) 1.05(0.81-1.36) 0.93(0.82-1.31) 1.05(0.81-1.36) 0.93(0.82-1.31) 1.05(0.81-1.36) 0.93(0.82-1.31) 1.05(0.81-1.36) 0.93(0.82-1.31) 1.05(0.81-1.36) 0.93(0.82-1.31) 1.05(0.81-1.36) 0.93(0.82-1.31) 1.05(0.81-1.36) 0.93(0.82-1.31) 1.05(0.81-1.36) 0.93(0.82-1.31) 1.05(0.81-1.36) 0.93(0.82-1.31) 1.05(0.82-1.31) 1.0$

1.40) $P_{interaction} = 0.039$,OR(95%CI) = 0.52(0.28-0.97) $P_{interaction} = 0.196$

Note: ^a, *P* for interaction was calculated by Logistic Regression adjusted by gender, age and *H.pylori* infection status. CON: controls; AG: atrophic gastritis; GC: gastric cancer.

doi:10.1371/iournal.pone.0089203.t003

Table 4. The genotype combinations of the SNP-SNP interactions in three polymorphisms with the risk of atrophic gastritis^a.

SNP genotypes			CON(%)	AG(%)	P	OR(95%CI)
pri-let-7a-1	PGC	PGC	n	n		
rs10739971	rs6458238	rs9471643	717	646		
GG+AG	GA+AA	GC+CC	28	10		1
GG+AG	GA+AA	GG	75	66	0.026	2.46(1.11–5.45)
GG+AG	GG	GC+CC	233	212	0.014	2.55(1.21–5.37)
GG+AG	GG	GG	253	230	0.014	2.55(1.21–5.36)
AA	GA+AA	GC+CC	5	9	0.016	5.04(1.36–19.68)
AA	GA+AA	GG	28	9	0.843	0.90(0.32–2.55)
AA	GG	GC+CC	42	57	0.002	3.80(1.67–8.67)
AA	GG	GG	53	53	0.013	2.80(1.24–6.33)
						P _{interaction} = 0.001, OR(95%CI) = 23.55(3.73-148.71)

Note: ^a, *P* for interaction was calculated by Logistic Regression adjusted by gender, age and *H.pylori* infection status. CON: controls; AG: atrophic gastritis. doi:10.1371/journal.pone.0089203.t004

effects observed in this study were because of binding of miRNA and its target genes still requires further functional experiments.

This study had some limitations. First, although we had a relative large sample size of 471 gastric cancer patients, 645 atrophic gastritis patients and 717 controls, this sample size may still be inadequate for detecting interaction effects, particularly for rare alleles. Second, the mechanisms of the associated SNP-SNP interactions need to be clarified, and subsequent functional experiments are required. Third, several genome-wide association studies suggest an integration of data from genome-wide association studies of gastric cancer from Chinese populations; therefore, data should be integrated, and may be used as candidate polymorphism sites to be studied in the future. Fourth, the interaction between gene and environment for gastric cancer risk is an important factor to be considered, such as smoking and drinking. In this study, we collected some data on smoking and drinking, but there remains nearly a third of missing data from the samples. Interactions between genes and smoking and drinking behavior on gastric cancer risk should be examined.

References

- Xu Y, Liu L, Liu J, Zhang Y, Zhu J, et al. (2011) A potentially functional polymorphism in the promoter region of miR-34b/c is associated with an increased risk for primary hepatocellular carcinoma. Int J Cancer 128: 412–417.
- Zhang LS, Liang WB, Gao LB, Li HY, Li LJ, et al. (2012) Association between pri-miR-218 polymorphism and risk of hepatocellular carcinoma in a Han Chinese population. DNA Cell Biol 31: 761–765.
- Arisawa T, Tahara T, Shiroeda H, Matsue Y, Minato T, et al. (2012) Genetic polymorphisms of IL17A and pri-microRNA-938, targeting IL17A 3'-UTR, influence susceptibility to gastric cancer. Hum Immunol 73: 747–752.
- He C, Tu H, Sun L, Xu Q, Li P, et al. (2013) Helicobacter pylori-related host gene polymorphisms associated with susceptibility of gastric carcinogenesis: a two-stage case-control study in Chinese. Carcinogenesis 34: 1450–1457.
- Altmuller J, Palmer LJ, Fischer G, Scherb H, Wjst M (2001) Genomewide scans of complex human diseases: true linkage is hard to find. Am J Hum Genet 69: 936–950.
- Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K (2002) A comprehensive review of genetic association studies. Genet Med 4: 45–61.
- Moore JH, Williams SM (2002) New strategies for identifying gene-gene interactions in hypertension. Ann Med 34: 88–95.
- Cordell HJ (2009) Detecting gene-gene interactions that underlie human diseases. Nat Rev Genet 10: 392–404.
- 9. Moore JH (2003) The ubiquitous nature of epistasis in determining susceptibility to common human diseases. Hum Hered 56: 73-82.
- Liu L, Wu C, Wang Y, Zhong R, Wang F, et al. (2011) Association of candidate genetic variations with gastric cardia adenocarcinoma in Chinese population: a multiple interaction analysis. Carcinogenesis 32: 336–342.

Conclusion

This study, for the first time, reports that pri-let-7a-1 rs10739971 polymorphism and *ERCC6* rs1917799 polymorphism might have an interaction effect on gastric cancer risk; and pri-let-7a-1 rs10739971 polymorphism might have an interaction effect with *PGC* rs6458238 and rs9471643 polymorphisms on atrophic gastritis risk. Some data have been collected providing for the possible construction of a gastric cancer network pathway. Future large-scale studies and mechanism experiments are required to confirm the findings of this study.

Author Contributions

Conceived and designed the experiments: YY. Performed the experiments: QX YG JJ. Analyzed the data: CH LS. Contributed reagents/materials/analysis tools: CH LS. Wrote the paper: QX JL. Collected a part of the samples: CX.

- Sapkota Y, Mackey JR, Lai R, Franco-Villalobos C, Lupichuk S, et al. (2013)
 Assessing SNP-SNP interactions among DNA repair, modification and metabolism related pathway genes in breast cancer susceptibility. PLoS One 8: e64896.
- Link A, Kupcinskas J, Wex T, Malfertheiner P (2012) Macro-role of microRNA in gastric cancer. Dig Dis 30: 255–267.
- Mishra PJ, Bertino JR (2009) MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine. Pharmacogenomics 10: 399–416.
- Ning PF, Liu HJ, Yuan Y (2005) Dynamic expression of pepsinogen C in gastric cancer, precancerous lesions and Helicobacter pylori associated gastric diseases. World J Gastroenterol 11: 2545–2548.
- Pines A, Hameetman L, de Wilde J, Alekseev S, de Gruijl FR, et al. (2010) Enhanced global genome nucleotide excision repair reduces UV carcinogenesis and nullifies strand bias in p53 mutations in Csb-/- mice. J Invest Dermatol 130: 1746–1749.
- Liu J, He C, Sun L, Xu Q, Xing C, et al. (2013) ERCC6 rs1917799 T>G
 polymorphism associated with susceptibility to gastric cancer in Chinese
 population: a case-control study. Asian Pacific Journal of Cancer Prevention/accepted).
- Zhu YM, Zhong ZX, Liu ZM (2010) Relationship between let-7a and gastric mucosa cancerization and its significance. World J Gastroenterol 16: 3325– 3329
- Wang WN, Chen Y, Zhang YD, Hu TH (2013) The regulatory mechanism of CCR7 gene expression and its involvement in the metastasis and progression of gastric cancer. Tumour Biol 34: 1865–1871.

- Xu Q, Yuan Y, Sun LP, Gong YH, Xu Y, et al. (2009) Risk of gastric cancer is associated with the MUC1 568 A/G polymorphism. Int J Oncol 35: 1313–1320.
- Liu JW, He CY, Sun LP, Xu Q, Xing CZ, et al. (2013) The DNA Repair Gene ERCC6 rs1917799 Polymorphism is Associated with Gastric Cancer Risk in Chinese. Asian Pac J Cancer Prev 14: 6103–6108.
- Gong YH, Sun LP, Jin SG, Yuan Y (2010) Comparative study of serology and histology based detection of Helicobacter pylori infections: a large populationbased study of 7,241 subjects from China. Eur J Clin Microbiol Infect Dis 29: 907–911.
- Zhong R, Liu L, Zou L, Sheng W, Zhu B, et al. (2013) Genetic variations in the TGFbeta signaling pathway, smoking and risk of colorectal cancer in a Chinese population. Carcinogenesis 34: 936–942.
- Liu L, Wu J, Zhong R, Wu C, Zou L, et al. (2013) Multi-loci analysis reveals the importance of genetic variations in sensitivity of platinum-based chemotherapy in non-small-cell lung cancer. Mol Carcinog 52: 923–931.
- Chen W, Song H, Zhong R, Zhu B, Guo H, et al. (2013) Risk of GWASidentified genetic variants for breast cancer in a Chinese population: a multiple interaction analysis. Breast Cancer Res Treat 142: 637–644.
- He CY, Sun LP, Gong YH, Xu Q, Dong NN, et al. (2011) Serum pepsinogen II: a neglected but useful biomarker to differentiate between diseased and normal stomachs. J Gastroenterol Hepatol 26: 1039–1046.